PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 28(Supplement_2): 33-37 2008
© 2008 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banks, M.
Right arrow Articles by Sprague, S. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Banks, M.
Right arrow Articles by Sprague, S. M.

INVITED REVIEWS

VITAMIN D AND PERITONEAL DIALYSIS

Mindy Banks and Stuart M. Sprague

Division of Nephrology and Hypertension, Evanston Northwestern Healthcare and Northwestern University, Feinberg School of Medicine, Evanston, Illinois

Correspondence to: S.M. Sprague, Northwestern University, Feinberg School of Medicine, and Evanston Northwestern Healthcare, 2650 Ridge Avenue, Evanston, Illinois 60201 U.S.A. ssprague{at}northwestern.edu

Chronic kidney disease – mineral and bone disorder (CKD–MBD) is a cause of significant morbidity and mortality in patients with long-standing kidney disease. Management of secondary hyperparathyroidism includes the use of phosphorus-binding agents and treatment with activated vitamin D compounds, better referred to as vitamin D receptor agonists (VDRAs). In an effort to maximize the therapeutic response while reducing the adverse effects of calcitriol, the naturally synthesized hormone, the use of intravenous administration and several selective VDRAs have been developed. Recently, oral preparations of these selective VDRAs have become available, enabling their use in the peritoneal dialysis (PD) population. The present report reviews the data concerning the use of oral VDRAs for the treatment of hyperparathyroidism in PD patients. The data, although limited, appear to support the use of oral paricalcitol as the VDRA in PD patients. In addition, traditional teaching focuses only on therapy with VDRAs, ignoring vitamin D replacement in CKD stage 5. However, given the potential benefits of calcidiol (25-OH-D) repletion and the rampant 25-OH-D deficiency in the PD population, our opinion is that screening for and treating that deficiency should extend beyond early CKD and also include PD patients.

KEY WORDS: Chronic kidney disease–mineral and bone disorder; hyperparathyroidism; vitamin D; vitamin D receptor agonists.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 2008 by Multimed Inc.